Risk-benefit assessment of methotrexate in the treatment of severe psoriasis

American Journal of Clinical Dermatology
A L Kuijpers, P C Van de Kerkhof

Abstract

Methotrexate is an established and highly effective systemic treatment for severe psoriasis, including the pustular and erythrodermic forms. It has been widely used during the last 3 decades. For this reason, the long term adverse effects of methotrexate are well known, in contrast to other relatively new systemic treatments like cyclosporin and retinoids. The most frequent adverse effects occurring during methotrexate therapy are abnormal liver function tests, nausea and gastric complaints. The most feared adverse effects are myelosuppression and hepatotoxicity. Because hepatotoxicity is related to a high cumulative dose of methotrexate, rotational therapy or an intermittent instead of a continuous treatment schedule are advised. The histological assessment of liver biopsies, according to the international guidelines, remains the gold standard for detection of liver damage until equally reliable noninvasive screening methods for liver damage--tentatively dynamic hepatic scintigraphy (DHS) or measurement of levels of serum aminoterminal propeptide of type III procollagen--are well evaluated. Low dose methotrexate therapy is relatively well tolerated, provided that there is careful patient selection and regular monitoring for ad...Continue Reading

References

Jul 5, 1979·The New England Journal of Medicine·D J ProckopN A Guzman
Jan 1, 1979·Cancer Chemotherapy and Pharmacology·W H SteeleJ G McVie
Jul 1, 1976·The Journal of Investigative Dermatology·G D Weinstein, J L McCullough
May 1, 1977·Archives of Dermatology·J R Taylor, K M Halprin
Jul 1, 1992·Clinical and Experimental Dermatology·P Collins, S Rogers
Jun 1, 1992·International Journal of Dermatology·A C VerschuurR A Chamuleau
Mar 1, 1992·Journal of the American Academy of Dermatology·M H Kanzler, D Gorsulowsky
Jan 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·P M SchwartzL M Milstone
Aug 1, 1991·The Journal of Allergy and Clinical Immunology·M F Mullarkey
Apr 1, 1990·The British Journal of Dermatology·J J Leyden
Apr 1, 1990·The British Journal of Dermatology·J P Ortonne
Jun 1, 1990·The British Journal of Dermatology·M S FradinJ J Voorhees
Sep 1, 1990·Clinical and Experimental Dermatology·H Groenendal, F H Rampen
Sep 1, 1990·Journal of Clinical Pharmacology·F G LarsenK Kragballe
Nov 1, 1990·Drugs·J P Tung, H Maibach
Apr 1, 1989·Arthritis and Rheumatism·R SegalB Tartakovsky
Jun 14, 1986·Lancet·R R SinghJ S Guleria
Jul 1, 1988·Journal of the American Academy of Dermatology·H RoenigkG D Weinstein
Jan 4, 1986·British Medical Journal·S H SaverymuttuJ D Maxwell
Sep 1, 1988·The British Journal of Dermatology·J RisteliH Zachariae
Dec 1, 1988·The British Journal of Dermatology·J ParamsothyC M Lawrence
Mar 1, 1988·Clinical and Experimental Dermatology·P Duhra, I S Foulds
May 1, 1988·Arthritis and Rheumatism·R J RothenbergA G Finesilver
Jul 1, 1987·Clinical and Experimental Dermatology·D MitchellR J Chalmers
Dec 1, 1987·Journal of the American Academy of Dermatology·D R ThomasR D Camp
Aug 1, 1987·The Journal of Investigative Dermatology·T TernowitzK Kragballe
Jan 1, 1987·Dermatologica·H Zachariae, H Søgaard
Sep 1, 1987·The British Journal of Dermatology·M RademakerD D Munro
Jun 1, 1986·Archives of Dermatology·S K JonesJ E White
Mar 28, 1985·The New England Journal of Medicine·M E WeinblattD E Trentham
Jan 1, 1985·Journal of Hepatology·S SherlockD J Van Leeuwen
Jan 1, 1985·Clinical and Experimental Dermatology·J Hendel, A Nyfors
May 1, 1985·The British Journal of Surgery·M I McLarenS J Karran
May 1, 1985·Clinical and Experimental Dermatology·P C Van de KerkhofJ W Mali
Jun 1, 1974·The Journal of Investigative Dermatology·L T ReeseA Z Eisen
Nov 1, 1980·Lancet·A I ShortJ S Robson
Jan 1, 1984·Journal of the American College of Nutrition·A J BarakH C Beckenhauer
Jan 1, 1984·Pharmacology & Therapeutics·R C Jackson
Sep 1, 1984·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·A FreiK Weigand
Oct 1, 1983·Archives of Dermatology·J D Adams
Jan 1, 1984·European Journal of Clinical Pharmacology·J Hendel, A Nyfors
Jun 1, 1983·Archives of Dermatology·G D Weinstein
Aug 1, 1980·Journal of the American Academy of Dermatology·C G Burkhart
Oct 1, 1982·The Journal of Investigative Dermatology·R E AshtonJ E White
Sep 1, 1982·Clinical and Experimental Dermatology·L HendelE Gudmand-Høyer
Dec 1, 1982·Journal of the American Academy of Dermatology·B S PaulJ A Parrish
Apr 1, 1980·The British Journal of Dermatology·H ZachariaeH Søgaard
May 1, 1980·International Journal of Dermatology·S N Creswell, D Burrows
May 1, 1980·European Journal of Clinical Pharmacology·J R LawrenceB Whiting
Aug 31, 1995·The New England Journal of Medicine·R U Hausknecht
Mar 2, 1995·The New England Journal of Medicine·M W Greaves, G D Weinstein
Sep 1, 1994·Pediatric Dermatology·B KumarI Kaur
Feb 1, 1994·The British Journal of Dermatology·R J Van Dooren-GreebeP C Van de Kerkhof
Nov 1, 1993·Journal of the American Academy of Dermatology·L F MorrisA K Silverman
Mar 1, 1993·Journal of the American Academy of Dermatology·G D Weinstein, G M White
Mar 1, 1993·Journal of the American Academy of Dermatology·P Duhra
Nov 1, 1995·The British Journal of Dermatology·M J BoffaD M Mitchell
Jan 1, 1996·Dermatology : International Journal for Clinical and Investigative Dermatology·H ZachariaeL Heickendorff
Nov 1, 1996·Journal of the American Academy of Dermatology·H P Pearce, B B Wilson
Dec 1, 1996·Arthritis and Rheumatism·B N Cronstein
Jan 1, 1996·Scandinavian Journal of Rheumatology·J M Kremer
Nov 1, 1996·Clinical and Experimental Dermatology·M J Boffa, R J Chalmers
Oct 6, 1997·Clinics in Dermatology·S SaidG D Weinstein
Mar 31, 1998·Journal of the American Academy of Dermatology·H RoenigkMark G Lebwohl
Aug 1, 1958·A.M.A. Archives of Dermatology·W F EDMUNDSON, W B GUY
Dec 1, 1951·A.M.A. Archives of Dermatology and Syphilology·R GUBNER
Nov 1, 1990·The Journal of Investigative Dermatology·G D WeinsteinJ L McCullough

Citations

Dec 4, 2012·Dermatology and Therapy·Bruce E StroberMelodie Young
Jun 7, 2005·Toxicology and Applied Pharmacology·Hsiu-Mei ChiangPei-Dawn Lee Chao
Jan 1, 2009·Clinical, Cosmetic and Investigational Dermatology·Rosita SaracenoSergio Chimenti
Jun 4, 2014·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Silvano AdamiGiampiero Girolomoni
Aug 13, 2013·Expert Opinion on Biological Therapy·Rosita SaracenoM S Chimenti
Jun 16, 2012·Toxicology and Applied Pharmacology·Shih-Ying YangYu-Chi Hou
Mar 19, 2011·Journal of the American Academy of Dermatology·Alyssa D SearlesSteven R Feldman
May 26, 2009·Medicina clínica·M Carmen Martínez-Raposo PiedrafitaCristina Navarro Pemán
Jul 14, 2006·Journal of the European Academy of Dermatology and Venereology : JEADV·P C Van de Kerkhof
May 17, 2006·International Journal of Dermatology·Kim A PappEfalizumab Study Group
Apr 1, 2008·The British Journal of Dermatology·Craig L LeonardiAlice B Gottlieb
Jun 26, 2009·Journal of the European Academy of Dermatology and Venereology : JEADV·A LyakhovitskyH Trau
Jun 15, 2005·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·Athanasios KalantzisEdward W Odell
Apr 2, 2005·Clinics in Dermatology·Edith OrionRonni Wolf
Jun 26, 2014·BioMed Research International·Jian-yuan LiMing-yu Sun
Jul 28, 2016·American Journal of Clinical Dermatology·Carolyn StullGil Yosipovitch
Aug 9, 2011·American Journal of Rhinology & Allergy·Seong Kook ParkDae Young Hur
Dec 3, 2003·Seminars in Cutaneous Medicine and Surgery·Jeffrey M Sobell, Stephen J Hallas
May 20, 2005·Seminars in Cutaneous Medicine and Surgery·Jeffrey M Sobell

Related Concepts

Immunosuppressive Agents
Methotrexate, (DL)-Isomer
Psoriasis
Severity of Illness Index
Benefit-Risk Assessment

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Spatio-Temporal Regulation of DNA Repair

DNA repair is a complex process regulated by several different classes of enzymes, including ligases, endonucleases, and polymerases. This feed focuses on the spatial and temporal regulation that accompanies DNA damage signaling and repair enzymes and processes.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Torsion Dystonia

Torsion dystonia is a movement disorder characterized by loss of control of voluntary movements appearing as sustained muscle contractions and/or abnormal postures. Here is the latest research.

Archaeal RNA Polymerase

Archaeal RNA polymerases are most similar to eukaryotic RNA polymerase II but require the support of only two archaeal general transcription factors, TBP (TATA-box binding protein) and TFB (archaeal homologue of the eukaryotic general transcription factor TFIIB) to initiate basal transcription. Here is the latest research on archaeal RNA polymerases.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.